To overcome the inherent challenge of translation termination interference caused by stop codon reprogramming in mammalian ...

To overcome the inherent challenge of translation termination interference caused by stop codon reprogramming in mammalian ...

To overcome the inherent challenge of translation termination interference caused by stop codon reprogramming in mammalian ...

We have proposed new amino acid secondary structure propensities in proteins with different folding types based on synonymous codons. They have been derived from 200 all alpha, all beta, alpha/beta, ...

The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety of mRNA technology, despite an extensive history of testing.

Fact check: HHS misleads on mRNA vaccine safety after pulling Moderna funding The safety of approved mRNA vaccines is well-established and, as with other vaccines, continues to be monitored by ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in all-stock transaction that values the acquired biotech at $1.25 billion.

BioNTech has agreed to acquire mRNA specialist CureVac for approximately $1.25bn, as the big pharma company amps up its strategy to offer cancer treatments using the modality.

In a move to reportedly consolidate and expand its capabilities in messenger RNA (mRNA)-based medicine, BioNTech has announced plans to acquire CureVac through an all-stock transaction valued at ...